Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (1700)	1/14/1998 10:19:00 PM
From: Anaxagoras	Read Replies (2) \| Respond to of 7041

<<Like I said previously, the in-house scientists did not review the drug in any way including its formulation. You may find this hard to believe, but it is absolutely true.>> Absolutely true? How did you verify this? And do you have evidence that this is also the case for the other three major pharms that also made offers? Sceptically yours, Anaxagoras

To: Bill Wexler who wrote (1700)	1/14/1998 10:57:00 PM
From: Myron David Kor	Respond to of 7041

I would like to know about the missing 132mg I would like to know about the missing 132mg I would like to know about the missing 132mg HOW MANY TIMES WILLIE BOY MUST I ASK?

To: Bill Wexler who wrote (1700)	1/15/1998 9:16:00 AM
From: Anaxagoras	Respond to of 7041

Good morning, Bill. I see that you're up and posting. Since you haven't responded to my post, I was thinking maybe you just missed it. So here it is again. Thanks. ~~~~~~~~~~~~ You wrote: <<Like I said previously, the in-house scientists did not review the drug in any way including its formulation. You may find this hard to believe, but it is absolutely true.>> Absolutely true? How did you verify this? And do you have evidence that this is also the case for the other three major pharms that also made offers? Sceptically yours, Anaxagoras